Nalaganje...
Drug–Drug Interactions with the NS3/4A Protease Inhibitor Simeprevir
Simeprevir is an NS3/4A protease inhibitor approved for the treatment of hepatitis C infection, as a component of combination therapy. Simeprevir is metabolized by the cytochrome P450 (CYP) system, primarily CYP3A, and is a substrate for several drug transporters, including the organic anion transpo...
Shranjeno v:
| izdano v: | Clin Pharmacokinet |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Springer International Publishing
2015
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4756048/ https://ncbi.nlm.nih.gov/pubmed/26353895 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40262-015-0314-y |
| Oznake: |
Označite
Brez oznak, prvi označite!
|